Company Description
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States.
The company operates through two segments: Diagnostic Research and Development; and Laboratory Services.
The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease.
bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
| Country | United States |
| Founded | 2014 |
| IPO Date | Sep 1, 2022 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Maria Zannes |
Contact Details
Address: 3300 Nacogdoches Road, Suite 216 San Antonio, Texas 78217 United States | |
| Phone | 210 698 5334 |
| Website | bioaffinitytech.com |
Stock Details
| Ticker Symbol | BIAF |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.13 |
| CIK Code | 0001712762 |
| CUSIP Number | 09076W307 |
| ISIN Number | US09076W3079 |
| Employer ID | 46-5211056 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Maria Zannes J.D. | Founder, President, Chief Executive Officer and Director |
| Steven Girgenti | Founder and Executive Chairman of the Board |
| James Michael Edwards CPA, M.B.A. | Chief Financial Officer |
| Xavier T. Reveles M.S. | Chief Operating Officer |
| Dr. William Bauta Ph.D. | Chief Science Officer |
| Timothy P. Zannes J.D. | Executive Vice President, Secretary and General Counsel |
| Julie Anne Overton | Director of Communications |
| Dallas J. Coleman | Vice President of sales |
| Dr. Gordon Downie M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 18, 2026 | 8-K | Current Report |
| Jun 18, 2026 | 424B4 | Prospectus |
| Jun 16, 2026 | EFFECT | Notice of Effectiveness |
| Jun 16, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 16, 2026 | 8-K | Current Report |
| Jun 12, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 2, 2026 | 8-K | Current Report |
| May 27, 2026 | 8-K | Current Report |
| May 20, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 14, 2026 | 424B3 | Prospectus |